Two second generation tests are currently on the market: the Quantiferon-TB Plus and the T-SPOT.TB, which differ from the previous ones in that they use new antigens which are able to stimulate both CD4 and CD8+ [84,85,86]. This evidence concerns the gene CD4 and tuberculosis.